Search
Huahai Pharmaceutical: Risankizumab Injection, a Category 1 Therapeutic Biological Product, Earns Priority Review Status
2025-08-19 /
Read about 0 minute
Author：小编
The Risankizumab (HB0034) Injection, a groundbreaking product independently developed by Hua'ao Tai, a subsidiary of Huahai Pharmaceutical, has been fast-tracked for priority review and approval. This medication is intended for the treatment of adult patients with generalized pustular psoriasis (GPP) and is classified as a Category 1 therapeutic biological product. Notably, it represents the first domestically produced anti-IL-36R antibody in China. Given the absence of similar locally manufactured drugs in the global market, its approval would be a significant milestone, effectively bridging the existing market gap.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
